BioNotebook: Five public company financings; TherapeuticsMD, La Jolla, Biodel, AGTC, CymaBay
This article was originally published in Scrip
Executive Summary
It's difficult to be a biotechnology company that's trying to launch an initial public offering right now, but already public companies, including some that recently completed IPOs, continue to find a market for follow-on offerings.